This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, S. M. Articles by Jeun, S.-S. Search for Related Content PubMed PubMed Citation Articles by Kim, S. M. Articles by Jeun, S.-S.

Gene Therapy Using TRAIL-Secreting Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells against Intracranial Glioma

¹ Department of Biomedical Science, College of Medicine, and ² Department of Neurosurgery, Kangnam St. Mary's Hospital, The Catholic University of Korea; ³ Medipost Biomedical Research Institute, MEDIPOST Co., Ltd., Seoul, Korea; ⁴ Research Laboratories of Dong-A Pharmaceutical Co., Ltd., Yongin, Korea; and ⁵ Division of Molecular and Life Sciences, Pohang University of Science and Technology, Pohang, Korea

Requests for reprints: Sin-Soo Jeun, Department of Neurosurgery, Kangnam St. Mary's Hospital, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Korea. Phone: 822-590-2568; Fax: 822-3482-1853; E-mail: ssjeun{at}catholic.ac.kr.

Key Words: glioma • umbilical cord blood • mesenchymal stem cells • TRAIL • adenovirus

Adenovirus-mediated gene therapies against brain tumors have been limited by the difficulty in tracking glioma cells infiltrating the brain parenchyma. Human umbilical cord blood–derived mesenchymal stem cells (UCB-MSC) are particularly attractive cells for clinical use in cell-based therapies. In the present study, we evaluated the tumor targeting properties and antitumor effects of UCB-MSCs as gene delivery vehicles for glioma therapy. We efficiently engineered UCB-MSCs to deliver a secretable trimeric form of tumor necrosis factor-related apoptosis-inducing ligand (stTRAIL) via adenoviral transduction mediated by cell-permeable peptides. We then confirmed the migratory capacity of engineered UCB-MSCs toward tumor cells by an in vitro migration assay and by in vivo injection of UCB-MSCs into the tumor mass or the opposite hemisphere of established human glioma in nude mice. Moreover, in vitro coculture, experiments on Transwell plates, and in vivo survival experiments showed that MSC-based stTRAIL gene delivery has more therapeutic efficacy compared with direct injection of adenovirus encoding the stTRAIL gene into a tumor mass. In vivo efficacy experiments showed that intratumoral injection of engineered UCB-MSCs (MSCs-stTRAIL) significantly inhibited tumor growth and prolonged the survival of glioma-bearing mice compared with controls. These results suggest that human UCB-MSCs have potential use as effective delivery vehicles for therapeutic genes in the treatment of intracranial glioma. [Cancer Res 2008;68(23):9614–23]

This article has been cited by other articles:

				H Schulze-Bergkamen, A Weinmann, M Moehler, J Siebler, and P R Galle Novel ways to sensitise gastrointestinal cancer to apoptosis Gut, July 1, 2009; 58(7): 1010 - 1024. [Abstract] [Full Text] [PDF]

				M. R. Loebinger, A. Eddaoudi, D. Davies, and S. M. Janes Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer Cancer Res., May 15, 2009; 69(10): 4134 - 4142. [Abstract] [Full Text] [PDF]